Edwards Lifesciences (NYSE:EW) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• Edwards Lifesciences reported earnings of $0.67 per share, exceeding analysts' expectations of $0.62 by $0.05, with revenue of $1.53 billion, surpassing estimates of $1.49 billion.
• The company has updated its Q3 2025 EPS guidance to a range of $0.540-$0.600 and FY 2025 guidance to $2.400-$2.500.
• Several brokerages increased their target prices for Edwards Lifesciences, with Citigroup raising its target to $95.00 and Wells Fargo to $84.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) issued its earnings results on Thursday. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05, Zacks reports. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.25%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business earned $0.70 EPS. The firm's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences updated its Q3 2025 guidance to 0.540-0.60 EPS and its FY 2025 guidance to 2.400-2.500 EPS.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $4.12 during midday trading on Friday, hitting $79.92. 15,656,685 shares of the company's stock traded hands, compared to its average volume of 3,810,979. The firm has a fifty day moving average of $76.58 and a 200 day moving average of $73.56. The stock has a market capitalization of $46.88 billion, a price-to-earnings ratio of 11.50, a price-to-earnings-growth ratio of 4.02 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences has a 1 year low of $59.41 and a 1 year high of $83.00.

Analysts Set New Price Targets

Several brokerages have recently weighed in on EW. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $80.00 to $84.00 and gave the company an "overweight" rating in a research report on Friday. Citigroup restated a "buy" rating and issued a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Argus upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday. Finally, Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research report on Friday. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and an average target price of $85.00.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president owned 33,496 shares of the company's stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the transaction, the chief executive officer owned 58,284 shares of the company's stock, valued at approximately $4,366,054.44. The trade was a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,848 shares of company stock worth $2,314,488 in the last quarter. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

An institutional investor recently bought a new position in Edwards Lifesciences stock. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,587 shares of the medical research company's stock, valued at approximately $266,000. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.